Anavex Life Sciences Corp (AVXL)

[OFP]

The significance of the Anavex 2-73 mechanism of action in regards to both Central Nervous System patients and to Anavex equity investors (among others) is not that it works in ways like no other, that it has a unique mechanism of action. Instead, it is unique because IT WORKS.

So just to be clear. All the generic S1R agonist actions regarding cellular homeostasis and protein folding repair are not important because we'd expect any S1R agonist to do that. Instead, there's something in the secret sauce that just makes 2-73 better..yet to be defined and all based on an uncontrolled, selectively reported trial in 25-32 patients. Does that sum it up correctly?

[It is good you now realize the holes in the AVXL MOA narrative]